Alina Kuźniacka

Alina Kuźniacka

Auto-generated profile, based on publicly available information

Alina Kuźniacka

Medical University of Gdansk

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
MRMagdalena Ratajska
Magdalena Ratajska
MKMagdalena Koczkowska
Magdalena Koczkowska
MŻMonika Żuk
Monika Żuk
AGAdam Gorczyński
Adam Gorczyński
AKAlina Kuźniacka
Alina Kuźniacka
BWBartosz Wasag
Bartosz Wasag
Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer

21 May 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KKKatarzyna Klonowska
Katarzyna Klonowska
MRMagdalena Ratajska
Magdalena Ratajska
KCKarol Czubak
Karol Czubak
AKAlina Kuzniacka
Alina Kuzniacka
IBIzabela Brozek
Izabela Brozek
Piotr KozlowskiPiotr Kozlowski
Piotr Kozlowski
Only approximately 50% of all familial breast cancers can be explained by known genetic factors, including mutations in BRCA1 and BRCA2. One of the most extensively studied candidates for breast and/or ovarian cancer susceptibility is BARD1. Although it was suggested that large mutations may contribute substantially to the deleterious variants of BARD1, no systematic study of the large mutations in BARD1 has been performed. To further elucidate the role of large mutations in BARD1, we designed a multiplex ligation-dependent probe amplification (MLPA) assay and performed an analysis of 504 women with a familial breast and/or ovarian cancer and 313 patients with ovarian cancer. The investigation did not reveal any large mutations in the BARD1 gene. Although the analysis was not focused on identification of small mutations, we detected seven deleterious or potentially deleterious point mutations, which contribute substantially to the total number of BARD1 mutations detected so far. In conclusion, although we cannot exclude the presence of large mutations in BARD1, our study indicates that such mutations do not contribute substantially to the risk of breast and/or ovarian cancer. However, it has to be noted that our results may be specific to the Polish population.

1 June 2004 in Cancer Genetics and Cytogenetics
Verified
Journal Article
Closed access
AKAlina Kuźniacka
Alina Kuźniacka
FMFredrik Mertens
Fredrik Mertens
BSBodil Strömbeck
Bodil Strömbeck
JWJoop Wiegant
Joop Wiegant
NMNils Mandahl
Nils Mandahl

28 March 2020 in Virchows Archiv
Verified
Journal Article
Open access
PDF file
MBMichał Bieńkowski
Michał Bieńkowski
MKMichał Kunc
Michał Kunc
MIMariola Iliszko
Mariola Iliszko
AKAlina Kuźniacka
Alina Kuźniacka
MSMichal Studniarek
Michal Studniarek
?B????Wojciech Biernat
????Wojciech Biernat
Warthin tumour is the second most common benign neoplasm of salivary glands. Despite its relatively characteristic histology, it may sometimes mimic other lesions. Here, we report two female non-smoker patients diagnosed with low-grade mucoepidermoid carcinoma with oncocytic epithelium and prominent lymphoid (Warthin-like) stroma and with molecularly confirmed MAML2 rearrangement. In addition, we screened a consecutive series of 114 Warthin tumour cases by means of MAML2 break apart fluorescence in situ hybridization to assess its value in differential diagnosis. MAML2 rearrangement was detected in both mucoepidermoid carcinoma cases, while all Warthin tumours were negative. Taking into account the literature data, Warthin-like mucoepidermoid carcinomas are more frequently observed in women, while a slight male predominance and smoking history are typical for Warthin tumour. In addition, the patients with Warthin-like mucoepidermoid carcinoma were significantly younger than those with Warthin tumour. To conclude, Warthin-like mucoepidermoid carcinoma may usually be suspected based on histology, while the diagnosis can be confirmed by means of molecular assays such as FISH. The investigation of MAML2 status is particularly advised when Warthin tumour is considered in a young, non-smoking, female patient.

1 November 2014 in Journal of Applied Genetics
Verified
Journal Article
Open access
PDF file
MRMagdalena Ratajska
Magdalena Ratajska
MKMagdalena Krygier
Magdalena Krygier
Maciej StukanMaciej Stukan
Maciej Stukan
AKAlina Kuźniacka
Alina Kuźniacka
MKMagdalena Koczkowska
Magdalena Koczkowska
BWBartosz Wasag
Bartosz Wasag
The importance of proper mutational analysis of BRCA1/2 in individuals at risk for hereditary breast and ovarian cancer syndrome is widely accepted. Standard genetic screening includes targeted analysis of recurrent, population-specific mutations. The purpose of the study was to establish the frequency of germline BRCA1/2 mutations in a group of 134 unrelated patients with primary ovarian cancer. Next generation sequencing analysis revealed a presence of 20 (14.9 %) mutations, where 65 % (n = 13) were recurrent BRCA1 alterations included in the standard diagnostic panel in northern Poland. However, the remaining seven BRCA1/2 mutations (35 %) would be missed by the standard approach and were detected in unique patients. A substantial proportion (n = 5/12; 41 %) of mutation-positive individuals with complete family history reported no incidence of breast or ovarian cancer in their relatives. This observation, together with the raising perspectives for personalized therapy targeting BRCA1/2 signaling pathways indicates the necessity of comprehensive genetic screening in all ovarian cancer patients. However, due to the limited sensitivity of the standard genetic screening presented in this study (65 %) an application of next generation sequencing in molecular diagnostics of BRCA1/2 genes should be considered.

1 September 2015 in Oncology Reports
Verified
Journal Article
Closed access
MRMagdalena Ratajska
Magdalena Ratajska
MMMagdalena Matusiak
Magdalena Matusiak
AKAlina Kuzniacka
Alina Kuzniacka
BWBartosz Wasag
Bartosz Wasag
IBIzabela Brozek
Izabela Brozek
IIIrmgard Irminger-Finger
Irmgard Irminger-Finger
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications